UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

Leukemia, 2019-12, Vol.33 (12), p.2795-2804

2019

Volltextzugriff (PDF)

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Blood, 2019-01, Vol.133 (1), p.7-17

2019

Volltextzugriff (PDF)

Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check

Science translational medicine, 2017-04, Vol.9 (386)

Jonas, Brian A

2017

Volltextzugriff (PDF)

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

The lancet oncology, 2018-02, Vol.19 (2), p.216-228

2018

Volltextzugriff (PDF)

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

The lancet oncology, 2019-07, Vol.20 (7), p.984-997

2019

Volltextzugriff (PDF)

On the origin of relapse in AML

Science translational medicine, 2017-07, Vol.9 (398)

Jonas, Brian A

2017

Volltextzugriff (PDF)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Clinical cancer research, 2022-12, Vol.28 (24), p.5272-5279

2022

Volltextzugriff (PDF)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Journal of clinical oncology, 2022-03, Vol.40 (8), p.855-865

2022

Volltextzugriff (PDF)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Cancers, 2022-07, Vol.14 (15), p.3634

2022

Volltextzugriff (PDF)

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

American journal of hematology, 2021-02, Vol.96 (2), p.208-217

2021

Volltextzugriff (PDF)

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Blood, 2022-02, Vol.139 (8), p.1135-1146

2022

Volltextzugriff (PDF)

A new therapeutic target for myelofibrosis is cause for Gli

Science translational medicine, 2017-05, Vol.9 (392)

Jonas, Brian A

2017

Volltextzugriff (PDF)

From MDS/AML to iPSC and back again

Science translational medicine, 2017-03, Vol.9 (380)

Jonas, Brian A

2017

Volltextzugriff (PDF)

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Cancer, 2021-08, Vol.127 (16), p.2943-2953

2021

Volltextzugriff (PDF)

Targeting TP53 -Mutated Acute Myeloid Leukemia: Research and Clinical Developments

OncoTargets and therapy, 2022-01, Vol.15, p.423-436

2022

Volltextzugriff (PDF)

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia

American journal of hematology, 2019-07, Vol.94 (7), p.803-811

2019

Volltextzugriff (PDF)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Frontiers in oncology, 2021-03, Vol.11, p.649209-649209

2021

Volltextzugriff (PDF)

Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia

Leukemia & lymphoma, 2022-09, Vol.63 (11), p.2711-2714

2022

Volltextzugriff (PDF)

Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia

British journal of haematology, 2017-06, Vol.177 (5), p.791-799

2017

Volltextzugriff (PDF)

Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute‐designated cancer centers in California

Cancer, 2018-05, Vol.124 (9), p.1938-1945

2018

Volltextzugriff (PDF)

Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity

PloS one, 2016-07, Vol.11 (7), p.e0159189

2016

Volltextzugriff (PDF)

Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy

Leukemia research, 2022-11, Vol.122, p.106947-106947, Article 106947

2022

Volltextzugriff (PDF)

Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma

JNCI : Journal of the National Cancer Institute, 2019-01, Vol.111 (1), p.78-85

2019

Volltextzugriff (PDF)

Characterization of a multidisciplinary team’s role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia

Supportive care in cancer, 2023-04, Vol.31 (4), p.224-224, Article 224

2023

Volltextzugriff (PDF)

1 – 25 von 1.051

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(900)
Mit Volltextzugriff
(888)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(565)
Life Sciences & Biomedicine
(396)
Humans
(268)
Physical Sciences
(119)
Female
(113)
Male
(110)
Adult
(81)
Chemistry
(68)
Animals
(66)
Technology
(66)
Middle Aged
(63)
Hematology
(57)
Science & Technology - Other Topics
(57)
Aged
(54)
Biological And Medical Sciences
(50)
Multidisciplinary Sciences
(46)
Proteins
(46)
Oncology
(45)
Biochemistry & Molecular Biology
(44)
Surgery
(43)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(10)
... seit 90 Tagen
(30)

Menü

Weitere Dienste

Einstellungen

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

On the origin of relapse in AML

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

A new therapeutic target for myelofibrosis is cause for Gli

From MDS/AML to iPSC and back again

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Targeting TP53 -Mutated Acute Myeloid Leukemia: Research and Clinical Developments

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia

Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia

Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute‐designated cancer centers in California

Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity

Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy

Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma

Characterization of a multidisciplinary team’s role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia

Suchergebnisse filtern